Trial · NCT07906275
INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
NCT07906275, Phase 3, Not yet recruiting, University of Calgary
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632. Trials, record NCT07906275. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906275
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
- NCT number
- NCT07906275
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 800 participants, estimated
- Lead sponsor
- University of Calgary
- Conditions
- Stroke, Acute Ischemic, Medium Vessel Occlusion
- Interventions
- Mechanical Endovascular Thrombectomy, Intravenous Thrombolysis, Tenecteplase/Alteplase- depending upon availability at each treating centre
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | A change of functional dependence analyzed across the whole distribution of outcomes assessed on the modified Rankin Scale (mRS), | From enrollment to the Day 90 assessment - Day 90 outcomes are assessed in a blinded manner | Modified Rankin Scale (mRS) -which scores of 0 to 1 indicate a favourable outcome without or with symptoms but no disability, scores of 2 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death. |
| Secondary | Ordinal Modified Rankin Score at 30 days | telephone called performed by a " blinded assessor" between 23-37 days after randomization | Modified Rankin Scale (mRS) -which scores of 0 to 1 indicate a favourable outcome without or with symptoms but no disability, scores of 2 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death. |
| Secondary | 24-hour National Institute of Stroke Scale Score (NIHSS) | From enrollment (randomization ) to 18-56 hours (Day 2) | The National Institutes of Health Stroke Scale (NIHSS) is a standardized clinical assessment used by trained healthcare professionals to measure the severity of neurological impairment caused by a stroke.It evaluates 11 areas, including level of consciousness, gaze, visual fields, facial movement, arm and leg strength, coordination, sensation, language, speech and neglect. Scores range from 0 to 42, with higher scores indicating greater neurological impairment. The NIHSS is used during the initial assessment and subsequent reassessments to document changes in neurological status and support treatment and clinical decision-making. |
| Secondary | Difference between 24 hour and baseline National Institute of Stroke Scale Score (NIHSS) | From enrollment (randomization) to 18-56 hours (Day 2) | The National Institutes of Health Stroke Scale (NIHSS) is a standardized clinical assessment used by trained healthcare professionals to measure the severity of neurological impairment caused by a stroke.It evaluates 11 areas, including level of consciousness, gaze, visual fields, facial movement, arm and leg strength, coordination, sensation, language, speech and neglect. Scores range from 0 to 42, with higher scores indicating greater neurological impairment. The NIHSS is used during the initial assessment and subsequent reassessments to document changes in neurological status and support treatment and clinical decision-making. |
| Secondary | Final reperfusion quality (extended Thrombolysis in Cerebral Infarction (MeVO eTICI) scale) | From enrollment (randomization) to post EVT procedure. Completed by the Central Core lab at 30 days after randomization | The thrombolysis in cerebral infarction (TICI) grading system as a tool for determining the response of thrombolytic therapy for ischemic stroke. In neurointerventional radiology it is commonly used for patients post endovascular revascularization. |
| Secondary | Infarct volume on 18-56-hour scan | Completed by the Central Core lab at 30 days after randomization | The thrombolysis in cerebral infarction (TICI) grading system as a tool for determining the response of thrombolytic therapy for ischemic stroke. In neurointerventional radiology it is commonly used for patients post endovascular revascularization. |
| Secondary | The proportion of patients with Symptomatic intracranial hemorrhage from enrolment up to Day 4 | From enrollment ( randomization) to Day 4 | Serious Adverse events include the following events :results in death, life threatening,Requires inpatient hospitalization or prolongation of existing hospitalization,Results in persistent disability/incapacity,Is a congenital anomaly/birth defect, an important medical event that may not result in death, be life-threatening, or require hospitalization, but may jeopardize the participant and may require medical or surgical intervention to prevent an outcome listed in the SAE selection. |
| Secondary | Parenchymal hemorrhage (PH-1 and PH-2) | From enrollment ( randomization) to Day 4 | PH-1-2:( hemorrhage grading scale) homogeneous hyperdensity occupying over 30% of the infarct zone, with significant mass effect |
| Secondary | Safety Assessments of Serious Adverse Events (SAEs) from enrollment up to Day 4 | From enrollment ( randomization) to Day 4 | Serious Adverse events include the following events :results in death, life threatening,Requires inpatient hospitalization or prolongation of existing hospitalization,Results in persistent disability/incapacity,Is a congenital anomaly/birth defect, an important medical event that may not result in death, be life-threatening, or require hospitalization, but may jeopardize the participant and may require medical or surgical intervention to prevent an outcome listed in the SAE selection. |
| Secondary | The Ordinal shift of 7 levels of mRS at 90 days (mRS 5 and 6 will be collapsed in one category) | Done by telephone at the Day 90 assessment (Day 90 outcomes are assessed in a blinded manner) | Modified Rankin Scale (mRS) -which scores of 0 to 1 indicate a favourable outcome without or with symptoms but no disability, scores of 2 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906275
GET https://conductscience.org/api/trials/v1/NCT07906275/registered